Dose Insider / Glossary / Harmony Outcomes

Harmony OutcomesThe heart trial of albiglutide

Updated November 20, 2026 · 3 min read · Hernandez et al., Lancet 2018

Harmony Outcomes is the cardiovascular trial of albiglutide, a weekly GLP-1 medicine once sold as Tanzeum. It enrolled 9,463 adults aged 40 or older with type 2 diabetes and cardiovascular disease, at 610 sites in 28 countries, and gave them albiglutide or placebo on top of usual care.

7%Median 1.6 years, Albiglutide, major heart events
Major heart eventsHarmony Outcomes, % of patientsMEDIAN 1.6 YEARSAlbiglutide7%Placebo9%EVENTS PER 100 PERSON-YEARSAlbiglutide4.6Placebo5.9Major heart eventsHarmony Outcomes, % of patientsMEDIAN 1.6 YEARSAlbiglutide7%Placebo9%EVENTS PER 100 PERSON-YEARSAlbiglutide4.6Placebo5.9

Hazard ratio 0.78 over a median of 1.6 years.

On this page

Over a median of 1.6 years, a first heart attack, stroke or cardiovascular death occurred in 7% on albiglutide against 9% on placebo. It was published in The Lancet in 2018.1

How the trial was run

Albiglutide was given once a week at 30 to 50 mg, depending on blood sugar response and tolerability, and compared with a matching volume of placebo. Participants were screened from July 2015 to November 2016, and 4,731 were assigned to albiglutide and 4,732 to placebo.1

The trial was event-driven. On November 8, 2017, the investigators determined that 611 main-outcome events and a median follow-up of at least 1.5 years had been reached, and everyone returned for a final visit; the last one was on March 12, 2018.1 That is why it was much shorter than LEADER or REWIND, which ran for a median of 3.8 and 5.4 years.2,3

What it found

Hernandez et al., 2018.1

How to read the result

In absolute terms, 90 fewer people out of about 4,700 in each group had a major heart event, roughly 2 in every 100, over a median of 1.6 years. The rates per 100 person-years, 4.6 against 5.9, are the better way to compare it with longer trials, because they adjust for how long people were followed.1 A 2021 review places albiglutide among the long-acting GLP-1 medicines, which it says lower fasting blood sugar and HbA1c more than the short-acting ones.4

The safety counts

The report counted events often raised about GLP-1 medicines. Acute pancreatitis occurred in 10 people on albiglutide and 7 on placebo. Pancreatic cancer occurred in 6 and 5. Medullary thyroid carcinoma, the cancer behind the boxed warning on GLP-1 labels, occurred in no one in either group.1 Over a median of 1.6 years and with such small counts, the trial could not settle these questions, but it did not show a clear excess.

Among the heart trials

Its hazard ratio of 0.78 sits within the range of the other heart trials of GLP-1 medicines with the same three-part outcome: 0.87 for liraglutide in LEADER, 0.74 for semaglutide in SUSTAIN 6, 0.88 for dulaglutide in REWIND.2,3,5 Together they built the case that several GLP-1 medicines lower heart risk in people with type 2 diabetes and heart disease, a case later extended to people without diabetes by SELECT.6

Albiglutide today

We found no current label for albiglutide on DailyMed on November 20, 2026, so it is not a medicine people can be prescribed from a current U.S. label.7 The trial still counts as evidence for the class. People who need a weekly GLP-1 medicine for type 2 diabetes have options with heart indications on their labels: Ozempic, Trulicity and Victoza among them.2,3,8 Our page on Ozempic and Mounjaro compares the two most used weekly injections.

Limits

The trial was short, was funded by GlaxoSmithKline, the maker, and enrolled only people aged 40 or older with established cardiovascular disease.1

Sources

  1. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018;392:1519-1529. Funded by GlaxoSmithKline. doi:10.1016/S0140-6736(18)32261-X
  2. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med 2016;375:311-322. doi:10.1056/NEJMoa1603827
  3. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet 2019;394:121-130. doi:10.1016/S0140-6736(19)31149-3
  4. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab 2021;46:101102. doi:10.1016/j.molmet.2020.101102
  5. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med 2016;375:1834-1844. doi:10.1056/NEJMoa1607141
  6. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023;389:2221-2232. doi:10.1056/NEJMoa2307563
  7. DailyMed, U.S. National Library of Medicine. Search for "albiglutide", no results; read November 20, 2026. dailymed.nlm.nih.gov
  8. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026, section 1; TRULICITY and VICTOZA prescribing information on DailyMed, section 1. accessdata.fda.gov

Related analyses

Log your doses, blood sugar and blood pressure in one place.

Open Dose Insider